Shares of Danaher Co. (NYSE:DHR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $276.88.
A number of research firms have recently issued reports on DHR. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Stifel Nicolaus boosted their price target on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Barclays raised their target price on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Royal Bank of Canada increased their price target on shares of Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th.
Check Out Our Latest Report on Danaher
Insider Buying and Selling at Danaher
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC grew its holdings in Danaher by 20.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after buying an additional 1,533 shares in the last quarter. Cercano Management LLC grew its position in shares of Danaher by 11.4% during the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after purchasing an additional 20,715 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Danaher by 48.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after purchasing an additional 96,395 shares during the period. Donaldson Capital Management LLC boosted its stake in Danaher by 5.8% during the first quarter. Donaldson Capital Management LLC now owns 1,469 shares of the conglomerate’s stock valued at $367,000 after buying an additional 80 shares during the period. Finally, Caden Capital Partners LP grew its position in Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after buying an additional 15,313 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.
Danaher Trading Down 2.7 %
Shares of Danaher stock opened at $269.35 on Thursday. The company’s fifty day moving average price is $256.29 and its two-hundred day moving average price is $251.12. The firm has a market capitalization of $194.53 billion, a PE ratio of 45.70, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. Danaher has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.05 earnings per share. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, analysts expect that Danaher will post 7.59 EPS for the current year.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- What is a SEC Filing?
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- P/E Ratio Calculation: How to Assess Stocks
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.